TrialThe Lancet. Oncology2022

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.

Robin Kate Kelley et al.PubMed ↗Publisher ↗

No numbers read from the abstract.